NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression
- PMID: 15314694
- PMCID: PMC503772
- DOI: 10.1172/JCI21358
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression
Abstract
The transcription factor NF-kappaB is activated in a range of human cancers and is thought to promote tumorigenesis, mainly due to its ability to protect transformed cells from apoptosis. To investigate the role of NF-kappaB in epithelial plasticity and metastasis, we utilized a well-characterized in vitro/in vivo model of mammary carcinogenesis that depends on the collaboration of the Ha-Ras oncoprotein and TGF-beta. We show here that the IKK-2/IkappaBalpha/NF-kappaB pathway is required for the induction and maintenance of epithelial-mesenchymal transition (EMT). Inhibition of NF-kappaB signaling prevented EMT in Ras-transformed epithelial cells, while activation of this pathway promoted the transition to a mesenchymal phenotype even in the absence of TGF-beta. Furthermore, inhibition of NF-kappaB activity in mesenchymal cells caused a reversal of EMT, suggesting that NF-kappaB is essential for both the induction and maintenance of EMT. In line with the importance of EMT for invasion, blocking of NF-kappaB activity abrogated the metastatic potential of mammary epithelial cells in a mouse model system. Collectively, these data provide evidence of an essential role for NF-kappaB during distinct steps of breast cancer progression and suggest that the cooperation of Ras- and TGF-beta-dependent signaling pathways in late-stage tumorigenesis depends critically on NF-kappaB activity.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/503772/bin/JCI0421358.f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/503772/bin/JCI0421358.f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/503772/bin/JCI0421358.f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/503772/bin/JCI0421358.f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/503772/bin/JCI0421358.f5.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/503772/bin/JCI0421358.f6.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/503772/bin/JCI0421358.f7.gif)
![Figure 8](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/503772/bin/JCI0421358.f8.gif)
![Figure 9](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/503772/bin/JCI0421358.f9.gif)
Similar articles
-
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.J Cell Biol. 2002 Jan 21;156(2):299-313. doi: 10.1083/jcb.200109037. Epub 2002 Jan 14. J Cell Biol. 2002. PMID: 11790801 Free PMC article.
-
Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51. doi: 10.1016/j.drup.2008.07.001. Epub 2008 Aug 20. Drug Resist Updat. 2008. PMID: 18718806 Review.
-
Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies.Oncogene. 2010 Feb 11;29(6):831-44. doi: 10.1038/onc.2009.399. Epub 2009 Nov 23. Oncogene. 2010. PMID: 19935703
-
NF-kappaB and epithelial to mesenchymal transition of cancer.J Cell Biochem. 2008 Jun 1;104(3):733-44. doi: 10.1002/jcb.21695. J Cell Biochem. 2008. PMID: 18253935 Review.
-
Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.Clin Cancer Res. 2009 May 15;15(10):3557-67. doi: 10.1158/1078-0432.CCR-08-1656. Epub 2009 May 15. Clin Cancer Res. 2009. PMID: 19447876
Cited by
-
Traditional Chinese medicine for breast cancer treatment: a bibliometric and visualization analysis.Pharm Biol. 2024 Dec;62(1):499-512. doi: 10.1080/13880209.2024.2359105. Epub 2024 May 30. Pharm Biol. 2024. PMID: 38813803 Free PMC article. Review.
-
Regulation of the Function and Expression of EpCAM.Biomedicines. 2024 May 20;12(5):1129. doi: 10.3390/biomedicines12051129. Biomedicines. 2024. PMID: 38791091 Free PMC article. Review.
-
Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2. Signal Transduct Target Ther. 2024. PMID: 38763973 Free PMC article. Review.
-
ATRX and Its Prognostic Significance in Soft Tissue Sarcoma.Sarcoma. 2024 May 6;2024:4001796. doi: 10.1155/2024/4001796. eCollection 2024. Sarcoma. 2024. PMID: 38741704 Free PMC article.
-
Pleiotropic physiological functions of Piezo1 in human body and its effect on malignant behavior of tumors.Front Physiol. 2024 Apr 16;15:1377329. doi: 10.3389/fphys.2024.1377329. eCollection 2024. Front Physiol. 2024. PMID: 38690080 Free PMC article. Review.
References
-
- Orlowski RZ, Baldwin Jr. AS. NF-κB as a therapeutic target in cancer. Trends Mol. Med. 2002;8:385–389. - PubMed
-
- Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer. 2002;2:301–310. - PubMed
-
- Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998;16:225–260. - PubMed
-
- Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 2000;18:621–663. - PubMed
-
- Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 1999;18:6925–6937. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials